REGN — Regeneron Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Regeneron Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	7,863	8,497	16,072	12,173	13,117
Cost of Revenue
Gross Profit	7,081	7,377	13,634	10,613	11,301
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,654	4,921	7,125	7,434	9,070
Operating Profit	2,210	3,577	8,947	4,739	4,047
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,429	3,810	9,326	4,859	4,199
Provision for Income Taxes
Net Income After Taxes	2,116	3,513	8,075	4,338	3,954
Net Income Before Extraordinary Items
Net Income	2,116	3,513	8,075	4,338	3,954
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,116	3,513	8,075	4,338	3,954
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	18.5	30.5	72	40.5	36.4